Assertio Holdings, Inc.

Assertio Holdings, Inc. is a U.S.-based pharmaceutical company built around a small portfolio of marketed, approved products in oncology, neurology, and pain management. Its commercial model relies on a mix of direct sales force activity and omni-channel promotion, with ROLVEDON as the core branded product and Sympazan and other products supported through digital and remote promotion. The company has grown largely through acquisitions and licensing of established products rather than internal drug discovery. In 2025, it also simplified the portfolio by ceasing commercialization of Otrexup and divesting Assertio Therapeutics, leaving a more focused commercial platform centered on marketed specialty pharmaceuticals.

7,1 %

−25,6 %

−5,0 %

1.70

1.51

— Assertio Holdings, Inc.
%
Oncology supportive care45% Products used to reduce complications from cancer treatment, centered on ROLVEDON.
Neurology10% Neurology-focused branded therapy promoted through direct and omni-channel channels, mainly Sympazan.
Pain management40% Established pain and inflammation products including INDOCIN, SPRIX, and CAMBIA.
Royalty and licensing income5% Royalty revenue from licensed product rights, including CAMBIA in Canada.

Assertio sells primarily to healthcare providers and institutions that prescribe or administer specialty...

  • Hospitals and community oncology clinicsprimary

    They buy or administer ROLVEDON because it supports chemotherapy patients at risk of infection and febrile neutropenia.

  • Specialty prescribers in neurologysecondary

    They prescribe Sympazan for patients needing a branded neurology therapy and respond to omni-channel promotion and access support.

  • Pain management physiciansprimary

    They prescribe INDOCIN, SPRIX, and CAMBIA for pain and inflammation indications where branded access and familiarity matter.

  • Payors and pharmacy benefit decision-makersprimary

    They influence whether patients can access Assertio products through formulary placement, coverage, and reimbursement terms.

  • Licensing and distribution partnerssecondary

    They commercialize CAMBIA in Canada and generate royalty revenue for Assertio.

Assertio is headquartered in the United States and its commercial activity is primarily U.S...

  • •United States is the core commercial market for product sales and promotion
  • •U.S. payors materially affect access, reimbursement, and adoption
  • •Canada contributes royalty income through the CAMBIA license agreement
  • •Commercial infrastructure is built around U.S. specialty pharma selling channels
  • •Divestiture of Assertio Therapeutics simplified the operating footprint in 2025

Assertio’s strategy is to concentrate on a smaller set of differentiated, approved products and use commercial...

01
Grow ROLVEDON adoptionshort-term

ROLVEDON is the company’s core branded growth driver and the main source of commercial focus.

02
Optimize omni-channel commercializationmedium-term

Digital and remote promotion can extend reach for smaller specialty products without a large field footprint.

03
Simplify the portfolioshort-term

Removing lower-priority assets can reduce operating complexity and focus capital on higher-value products.

Assertio faces concentration risk because a relatively small portfolio means that changes in ROLVEDON, INDOCIN, or...

high

Dependence on ROLVEDON commercial performance

The company’s growth and commercial focus are centered on a single lead product, so any slowdown in uptake would have an outsized impact.

Scope
Oncology supportive care portfolio
Materiality
high
high

Payor access and reimbursement restrictions

Specialty pharmaceuticals often require favorable coverage and formulary placement to achieve broad patient access.

Scope
U.S. commercial portfolio
Materiality
high
high

Litigation and activist-related costs

The company disclosed ongoing litigation and activist campaigns that have generated significant legal and other fees.

Scope
SG&A and management attention
Materiality
high
medium

Generic and competitive erosion

Legacy pain products are vulnerable to lower-priced alternatives and market share loss over time.

Scope
INDOCIN, SPRIX, CAMBIA
Materiality
high
medium

Inventory and supply chain volatility

Product sales depend on timely inventory purchases, manufacturing, and distribution, which can create cost and cash flow swings.

Scope
Commercial operations
Materiality
medium
Revenue recognition and variable consideration
Net sales and gross-to-net deductions
Inventory step-up and write-downs
Gross margin and quarterly cost volatility
Deferred tax asset valuation allowance
Income tax expense and effective tax rate
Impairment of long-lived assets
Potential non-cash charges to earnings

Cyclerion Therapeutics, Inc.

CYCN · Pharmaceutical Preparations

LEXICON PHARMACEUTICALS, INC.

LXRX · Pharmaceutical Preparations

Minerva Neurosciences, Inc.

NERV · Pharmaceutical Preparations

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Silexion Therapeutics Corp

SLXN · Biological Products, (No Diagnostic Substances)

: 11/08/2026